Physician profile
Christopher Langston
NPI 1902295165
$50,583.37
in general payments reported to CMS, 2019-2025
25 companies · $3,883 in 2025
The $3,883 reported for 2025 was more than what 82% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,017 · 2020: $156 · 2021: $5,085 · 2022: $9,589 · 2023: $11K · 2024: $12K · 2025: $3,883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Food and Beverage: $8,135 · Travel and Lodging: $428 · Education: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,050.00 |
| Food and Beverage | $8,135.24 |
| Travel and Lodging | $428.35 |
| Education | $122.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $23,310.99 | 2021-2025 | Mavenclad, Mavenclad |
| Genentech USA, INC. | $10,707.37 | 2021-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Biogen, INC. | $10,069.63 | 2019-2025 | Tysabri, Vumerity |
| Tg Therapeutics, INC. | $2,624.83 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $710.90 | 2020-2025 | |
| Celgene Corporation | $536.66 | 2022-2025 | Zeposia |
| Alexion Pharmaceuticals, INC. | $424.82 | 2022-2025 | Ultomiris |
| Amgen INC. | $283.55 | 2024-2025 | Uplizna |
| E.R. Squibb & Sons, L.L.C. | $278.04 | 2021-2022 | |
| Lilly USA, LLC | $259.72 | 2024-2025 | Kisunla, Amyvid, Emgality |
| Genzyme Corporation | $157.22 | 2019-2025 | |
| Abbvie INC. | $144.04 | 2021-2024 | |
| Argenx US, INC. | $143.32 | 2025 | Vyvgart, Vyvgart Hytrulo |
| Eisai INC. | $124.99 | 2025 | |
| Sk Life Science, INC. | $124.99 | 2024 | Xcopri |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $121.84 | 2022 | |
| Janssen Pharmaceuticals, INC | $115.40 | 2021 | |
| Genentech, INC. | $109.00 | 2024 | Ocrevus |
| Itf Therapeutics LLC | $95.48 | 2025 | |
| Ani Pharmaceuticals, INC. | $89.42 | 2023-2025 | Purified Cortrophin Gel |
| Cycle Pharmaceuticals INC | $43.13 | 2025 | Bafiertam, Tascenso Odt |
| Horizon Therapeutics Plc | $42.84 | 2021-2023 | Uplizna |
| Sandoz INC. | $25.44 | 2023 | |
| Pfizer INC. | $23.80 | 2024 | |
| Grifols USA, LLC | $15.95 | 2023 | Gamunex-C |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Langston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.